All In Biotech

Drug Trial Radar · NCT00002597

Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

A PHASE III TRIAL OF THE STUDY OF ENDOCRINE THERAPY USED AS A CYTOREDUCTIVE AND CYTOSTATIC AGENT PRIOR TO RADIATION THERAPY IN GOOD PROGNOSIS LOCALLY CONFINED ADENOCARCINOMA OF THE PROSTATE

Last checked: Nov 19, 2026Latest source record: Jun 14, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,028 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,028

Actual

Start

Oct 1994

Primary completion

Jul 2011

Study completion May 14, 2018

Sponsor

Lead sponsor
Radiation Therapy Oncology GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Feb 27, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Radiation therapy (RT) uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using flutamide, goserelin, and leuprolide may fight prostate cancer by reducing the production of androgens. It is not yet known which regimen of antiandrogen therapy is most effective for prostate cancer. PURPOSE: Randomized phase III trial to study the effectiveness of radiation therapy with or without antiandrogen therapy in treating patients who have stage I or stage II prostate cancer.

Conditions

  • Prostate Cancer

Interventions

  • flutamideDrug

    Two 125 mg capsules (t.i.d., p.o.) beginning two months before RT and continuing until RT is completed.

  • ZoladexDrug

    3.6 mg s.c. monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.

  • LupronDrug

    7.5 mg IM (intramuscular) monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.

  • radiation therapyRadiation

    46.8 Gy (1.8 Gy/day four to five times a week \[26 fx\]) to regional lymphatics followed by 19.8 Gy (1.8 Gy/day x 11 fx) for a total of 66.6 Gy to the prostate. Prostate only may be treated in defined circumstances.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival Rate (10-year)Time frame: From date of randomization to 10 years

Locations

239 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Comprehensive Cancer Center

    Birmingham, Alabama

  • Huntsville Hospital System

    Huntsville, Alabama

  • Comprehensive Cancer Institute of Huntsville

    Huntsville, Alabama

  • MBCCOP - Gulf Coast

    Mobile, Alabama

  • Alabama Oncology, LLC

    Montgomery, Alabama

  • Radiation Oncology Associates of West Alabama

    Tuscaloosa, Alabama

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Arizona Cancer Center

    Tucson, Arizona

  • Mount Diablo Medical Center

    Concord, California

  • Cancer Center and Beckman Research Institute, City of Hope

    Duarte, California

  • California Cancer Center

    Fresno, California

  • Saint Agnes Cancer Center

    Fresno, California

  • Glendale Memorial Hospital and Health Center

    Glendale, California

  • Sutter Health Western Division Cancer Research Group

    Greenbrae, California

  • University of California San Diego Cancer Center

    La Jolla, California

  • Loma Linda University Medical Center

    Loma Linda, California

  • Veterans Affairs Medical Center - Long Beach

    Long Beach, California

  • USC/Norris Comprehensive Cancer Center and Hospital

    Los Angeles, California

  • Jonsson Comprehensive Cancer Center, UCLA

    Los Angeles, California

  • CCOP - Bay Area Tumor Institute

    Oakland, California

  • Cancer Care Center

    Pomona, California

  • Radiation Oncology Center - Sacramento

    Sacramento, California

  • Radiation Medical Group, Inc.

    San Diego, California

  • UCSF Cancer Center and Cancer Research Institute

    San Francisco, California

  • O'Connor Hospital

    San Jose, California

  • CCOP - Santa Rosa Memorial Hospital

    Santa Rosa, California

  • Memorial Hospital Cancer Center

    Colorado Springs, Colorado

  • University of Colorado Cancer Center

    Denver, Colorado

  • CCOP - Christiana Care Health Services

    Wilmington, Delaware

  • Walter Reed Army Medical Center

    Washington D.C., District of Columbia

  • Lykes Center for Radiation Therapy

    Clearwater, Florida

  • Halifax Medical Center

    Daytona Beach, Florida

  • Radiation Therapy Associates - Fort Myers

    Fort Myers, Florida

  • University of Florida Health Science Center

    Gainesville, Florida

  • Health First Holmes Regional Medical Center

    Melbourne, Florida

  • dVeterans Affairs Medical Center - Miami

    Miami, Florida

  • Sylvester Cancer Center, University of Miami

    Miami, Florida

  • Baptist Hospital of Miami

    Miami, Florida

  • CCOP - Mount Sinai Medical Center

    Miami Beach, Florida

  • Florida Radiation Oncology Group

    Orange Park, Florida

Showing 40 of 239 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.